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Summary
Phage display was used to identify homing peptides for blood vessels in a mouse model of HPV16-induced epidermal
carcinogenesis. One peptide, CSRPRRSEC, recognized the neovasculature in dysplastic skin but not in carcinomas. Two
other peptides, with the sequences CGKRK and CDTRL, preferentially homed to neovasculature in tumors and, to a lesser
extent, premalignant dysplasias. The peptides did not home to vessels in normal skin, other normal organs, or the stages
in pancreatic islet carcinogenesis in another mouse model. The CGKRK peptide may recognize heparan sulfates in tumor
vessels. The dysplasia-homing peptide is identical to a loop in kallikrein-9 and may bind a kallikrein inhibitor or substrate.
Thus, characteristics of the angiogenic vasculature distinguish premalignant and malignant stages of skin tumorigenesis.
Introduction (Arbeit et al., 1994); in the FVB/n strain background, they sponta-
neously develop epidermal squamous cell cancers (SCC) in a
Tumorigenesis is a multistage process that involves multiple multistage fashion (Coussens et al., 1996). Their skin appears
cell types (Hanahan and Weinberg, 2000). One contributory cell normal at birth but becomes hyperplastic within the first month,
type is the tumor endothelia that line blood and lymphatic ves- and focal dysplasias develop between 3 and 6 months of age.
sels (Ruoslahti, 2002). These cells form a tumor’s prerequisite These focal dysplasias are angiogenic and by one year, these
blood vascular system during angiogenesis and also line the lesions develop into invasive SCCs in about half of the mice.
two routes used by tumor cells to metastasize. Angiogenesis Progression is accompanied by the upregulation of pro-angio-
is already apparent in the premalignant lesions of human tumors genic factors such as VEGF (Smith-McCune et al., 1997) and
and transgenic mouse tumor models (Hanahan and Folkman, bFGF (Arbeit et al., 1996), and the model has called attention
1996). The new blood vessels in neoplasias are often structurally to the involvement of proteases from inflammatory mast cells
and functionally abnormal (Carmeliet and Jain, 2000; Pasqualini (Coussens et al., 1999) and other bone marrow-derived cells
et al., 2002) and may be at different stages of normal maturation (neutrophils and macrophages) in angiogenesis and tumor pro-
during physiological angiogenesis (Gee et al., 2003). gression (Coussens et al., 2000).
The K14-HPV16 transgenic tumor model expresses human In vivo phage display has revealed peptides that target tumor
endothelial cells (Arap et al., 1998) or tumor pericytes (Burg etpapillomavirus type 16 (HPV16) oncogenes under control of the
keratin-14 (K14) promoter. These mice express the HPV16 E6 al., 1999). A combination of in vivo and ex vivo phage display
(Hoffman et al., 2004) has further expanded the discriminatoryand E7 oncogenes in the basal cells of their squamous epithelia
S I G N I F I C A N C E
Antiangiogenic therapies for the treatment of cancers have the promise of high efficacy and low toxicity. The complex responses
to antiangiogenic therapy likely reflect our incomplete understanding of the alterations that blood vessels experience during tumor
development and of how tumor types might molecularly differ in their neovascular parameters. We have discovered peptides that
differentially recognize blood vessels at distinctive stages of tumor progression in squamous carcinogenesis, predicting neovascular
heterogeneity between premalignant and malignant stages. These peptides present a means to define molecular determinants
relevant to the varying responses to antiangiogenic therapies and could serve as vehicles for targeting imaging agents and therapeu-
tics to tumor blood vessels in a tumor type- and stage-specific manner.
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power of that methodology, yielding peptides that recognize a second ex vivo round and 48 clones from the subsequent in
vivo round (data not shown) to identify the CX7C peptides thatshared cell surface specificity among tumor blood vessels, tu-
mor cells, and bone marrow cells (Porkka et al., 2002) or tumor had been selected. Nine peptides that appeared most frequently
amongst the 96 phage display clones analyzed were chosenlymphatic endothelium and tumor cells (Laakkonen et al., 2002).
The goal of the present study was to evaluate the molecular for further examination.
To test the homing specificity of these peptide sequences,changes that occur in blood vessels as they develop from angio-
genic vessels in dysplasias to tumor blood vessels. Our aim to we intravenously injected purified phage displaying a particular
sequence into K14-HPV16 mice bearing protuberant tumors orcompare the vasculature in premalignant and malignant lesions
was motivated in part by studies in another mouse model (RIP- alternatively presenting with multifocal dysplasias but no tu-
mors. Both neoplastic tissues and normal control organs wereTag) demonstrating that the efficacy of certain angiogenesis
inhibitors varied as a function of stage: several inhibitors were collected and assayed for accumulation of phage. Phage dis-
playing the peptide CRAKSKVAC, which appeared with themost effective against angiogenic dysplasias (progenitors),
whereas other compounds were more effective against later highest frequency in both the ex vivo (5 times) and in vivo
sequence pools (15 times), were 1500-fold enriched in dysplas-stages (Bergers et al., 1999, 2003). Thus the premalignant (and
nascent tumor) vasculature may have distinctive qualities as tic skin relative to nonrecombinant control phage (data not
shown). However, phage displaying this peptide accumulatedcompared to those of the mature tumor vasculature. Indeed, this
study supports that proposition. Herein we isolate and describe with similar frequencies in skin, kidney, and brain (data not
shown), indicating that the CRAKSKVAC sequence homes tothree peptides in depth that home via the circulation to the
neovasculature. One recognizes a binding moiety that is prefer- an abundant signal in each of these organs and is not specific
to the skin lesions of interest here. Six other of the dysplasia-entially expressed in skin dysplasias, but is low or absent in
tumors and in normal vasculature. Two other peptides homed selected clones also differentiated poorly between the control
tissues and dysplastic skin in these tests. Altogether, 7 of theto tumors and to a lesser extent to dysplastic skin vasculature
of tumor-bearing mice. All three peptides variably home to other 9 dysplasia phage clones appeared to be responsible for the
overall enrichment of the pool in the control tissues observed intumor types growing in or under the skin, but none recognize
the vasculature of angiogenic dysplasias or tumors in the RIP- the final in vivo round (Figure 1A, right) and were not considered
suitable candidates for further study. The insert sequences in theTag transgenic mouse model of pancreatic islet carcinoma.
These results, and those reported in the accompanying paper two remaining phage clones were found to be highly selective for
dysplastic skin and did not appreciably home to normal organs.(Joyce et al., 2003 [this issue of Cancer Cell]) that similarly
profiles the vasculature in the RIP-Tag model, show that the One of these peptides, CNRRTKAGC, is closely related to a
previously described peptide that homes to tumor lymphaticvessels of premalignant and fully malignant lesions are distin-
guishable and that different tumors express distinct repertoires vessels (Laakkonen et al., 2002) and was not further analyzed
here. The second dysplasia-homing peptide, CSRPRRSEC, wasof molecular markers in their vasculature.
novel in our experience; it appeared three times amongst the
48 phage sequenced from the in vivo round, along with twoResults
variants: CSRPRRSVC and CSRPRRSWC that appeared one
time each. Phage displaying the CSRPRRSEC peptide wereSelecting phage that home to dysplastic skin
We used a previously described library of T7 bacteriophage enriched 350-fold in dysplastic skin and did not significantly
accumulate in the control tissues (Figure 1C). When injectedthat display on their surface 9-mer cyclic peptides with seven
degenerate positions (CX7C) (Laakkonen et al., 2002). To isolate into a K14-HPV16 mouse bearing an ear tumor as well as
multifocal skin dysplasias, the CSRPRRSEC phage effectivelypeptides specific for dysplasia, we performed two rounds of
selection ex vivo and one round in vivo. For the ex vivo rounds, homed to dysplastic chest skin and dysplastic ear skin, but
showed little homing to the tumor (Figure 1C). The peptide-we incubated the phage with dispersed cells from dysplastic
skin removed from the ears and chest of K14-HPV16 mice at bearing phage did not home to the normal skin of FVB/n mice
in vivo (Figure 1C) and did not bind in ex vivo experiments to4–6 months of age. The biopsied lesions typically included a
focal region of epidermal dysplasia flanked by adjacent hyper- the hyperplastic skin of 1- to 2-month-old K14-HPV16 mice
(data not shown). These results indicate that the CSRPRRSECplastic epidermis, along with the underlying reactive stromal
elements and angiogenic endothelium in the aberrant dermis. peptide selectively homes to dysplastic lesions; we infer that
the CSRPRRSEC peptide binds to a molecule (a “receptor”)A portion of each tissue biopsy used for ex vivo or subsequent
in vivo rounds of phage selection was fixed in formalin and, that is present in skin dysplasias, but is essentially absent or
inaccessible via the circulation in normal skin or in SCCs.after conventional processing, examined histologically to assess
the neoplastic grade. H&E-stained paraffin sections confirmed
that the areas of skin used in these selection steps were largely Tumor-specific homing phage
To isolate phage that home to SCCs in K14-HPV16 mice, wecomprised of focal dysplasias (data not shown). The sequential
ex vivo selections on cell suspensions of dysplastic skin resulted performed two rounds of ex vivo and two rounds of in vivo
selections on tumors histologically confirmed as squamous cellin a 160-fold enrichment of phage relative to similar treatment
with nonrecombinant phage that lack displayed peptides (Figure carcinoma grades II–IV (Coussens et al., 1996). The enrichment
rose from 6-fold in the second ex vivo round to greater than1A, left); a greater than 10,000-fold enrichment resulted from
the subsequent in vivo round (Figure 1A, right). Selection in vivo 70-fold in the second in vivo round (the fourth sequential round
overall) (Figure 1B). Fifteen phage clones were selected for fur-also produced a minor enrichment of phage that homed to
the control tissues: brain, kidney, and hyperplastic skin. We ther analysis based on their frequent appearance amongst 192
sequenced clones (48 from ex vivo round 2, 48 from in vivo roundperformed DNA sequence analysis of 48 clones isolated in the
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Figure 1. Phage-displayed peptides home to dysplastic skin lesions and tumors
Ex vivo and in vivo selections of phage for binding and homing to dysplastic skin lesions (A) or tumors (B).
C: In vivo homing of the CSRPRRSEC from the dysplastic skin screen to dysplastic skin lesions of a 4- to 6-month-old K14-HPV16 mouse (left) and to dysplastic
skin lesions and tumor of a 9- to 12-month-old K14-HPV16 mouse (right).
In vivo homing of CGKRK (D) and CDTRL (E) peptides from tumor screening to tumors and other tissues in K14-HPV16 mice. Results from two different tumor-
bearing mice are shown for each peptide. The normal skin values shown in C–E are from parallel experiments in wild-type FVB/n mice.
1, and 96 from in vivo round 2) and their increased appearance in SCCs and dysplastic lesions; in one experiment, the phage
the in vivo rounds. Of these, four clones with amino acid se- accumulated more effectively in dysplastic lesions than in a
quences CGKRK, CGTKRKC, CDTAVVEGL, and CDTRL bound tumor, whereas the reverse was true in another experiment
to a K14-HPV16 tumor-derived cell suspension ex vivo. Phage- (Figure 1E). This phage showed little affinity for hyperplastic
displayed CDTAVVEGL also homed in vivo 340-fold to tumors skin and no significant homing to normal skin from FVB/n mice
(data not shown), but we had difficulties with the CDTAVVEGL (Figure 1E). Thus, phage displaying this peptide were variably
peptide in the subsequent steps, so we could not work further selective for both dysplasias and squamous tumors of the epi-
with the peptide. The remaining three phage-displayed pep- dermis, indicative of lesional heterogeneity in the moiety to
tides, CDTRL and the related CGKRK and CGTKRKC, were which it binds. The squamous cancers that arise in the HPV16
analyzed in depth.
model are heterogeneous, showing variations that can be
When intravenously injected into tumor-bearing K14-HPV16
scored by classical grading schemes for squamous tumorsmice, the CGKRK phage showed a marked preference for the
(Grades I–IV), as reported in Coussens et al. (1996); in addition,tumor, with an efficiency that varied from 80- to 1,000-fold
distinctive sebaceous cell carcinomas arise. Furthermore, thein two experiments. Some homing to dysplastic lesions was
angiogenic dysplasias undergo morphological progression asobserved in one of two experiments that showed an 80 enrich-
the lesions progress from hyperplasia to low to high grade dys-ment in the tumor (Figure 1D). Normal and hyperplastic skin
plasia, and thus it would not be surprising if there was variabilityand various control organs also accumulated CGKRK phage
in expression of certain binding moieties as a function of bothbut at very low levels (Figure 1D and data not shown). Similar
analysis of the CDTRL phage revealed a variable preference for premaligant and malignant progression.
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Figure 2. Vascular localization of homing phage
K14-HPV16 mice with dysplastic skin lesions or tumors were intravenously injected with individual homing phage, the mice were sacrificed 10 min later, and
the phage were detected in tissue sections with rabbit anti-T7 phage (red; Alexa594). Blood vessels were stained with rat anti-mouse CD31 (green; Alexa488).
A: CSRPRRSEC-displaying phage colocalizes with CD31 in the dysplastic skin lesions of 4- to 6-month-old dysplastic mice. B–E: The tumor-homing KRK-
containing phage (B and D) and CDTRL (C and E) phage home to CD31-positive vessels in skin tumor (B and C) and dysplasia (D and E). Original
magnifications: 400 (A and E), 200 (B–D).
Intra-tissue localization of homing peptides MECA32 in their target neoplastic tissue after an intravenous
injection and were not detected in tissues where the corre-To begin characterizing the nature of the selectivity of the dys-
plasia- and tumor-homing peptides for these neoplastic lesions, sponding phage did not home. Fluorescein-CSRPRRSEC colo-
calized with MECA32 in dysplastic skin vasculature from bothwe sought to visualize their localization using histological proce-
dures. K14-HPV16 mice were intravenously injected with cloned non-tumor-bearing (Figure 3A) and tumor-bearing mice (Figure
3D, inset); notably, the peptide was not detected within thephage displaying a particular peptide or with the chemically
synthesized, fluorescein-labeled peptide. We first evaluated the squamous tumor in the latter (Figure 3D), confirming its selectiv-
ity for the premalignant dysplastic vasculature. In contrast, thephage, intravenously injecting 4- to 6-month-old dysplasia-
bearing mice with the dysplasia-homing phage, presenting fluorescein-labeled CGKRK (Figure 3B) and CDTRL (Figure 3C)
peptides were not detected in the dysplastic skin of youngerCSRPRRSEC. In parallel, a set of 9- to 12-month-old tumor-
bearing mice were infused with one or the other of the tumor- non-tumor-bearing mice but were primarily detected in tumor
vasculature (Figures 3E and 3F) and at lower levels in the dys-homing phage, CGTKRKC, CGKRK, or CDTRL. Various tissues
were collected from each mouse and subjected to double label plastic skin of these tumor-bearing mice (data not shown).
Again, H&E staining of serial sections guided morphologicalimmunohistochemical staining, with an anti-T7 antibody to de-
tect phage and with an anti-CD31 antibody that marks the endo- evaluation of the binding patterns (see Supplemental Figure
S2 on Cancer Cell website). A fluorescein-conjugated controlthelial cells of the vasculature. In each case, the phage coloca-
lized with CD31-positive endothelial cells in the target tissue: peptide (NSSSVDK) did not home to any tissue. Taken together
with the immunolocalization analyses of phage homing, the pep-CSRPRRSEC in dysplastic skin (Figure 2A) and CGKRK (Figure
2B) and CDTRL (Figure 2C) in tumors. The CGTKRKC phage tide localization data indicate that CGKRK and CDTRL home
specifically to blood vessels in SCCs and in the dysplastic fociwas also detected to a lesser extent in the dysplastic skin of a
tumor-bearing mouse (Figure 2D), and the positive vessels were of tumor-bearing mice, but not to the vasculature of earlier stage
dysplasias in non-tumor-bearing mice.often around what appeared to be concentric, nested clusters
of keratinocytes, while the CDTRL phage was observed in large,
dilated vessels throughout the dysplastic and hyperplastic skin Tumor type specificity of peptide homing
The peptides identified by their binding to endothelial cells in(Figure 2E). Hematoxylin and eosin staining of serial sections
adjacent to those used to visualize phage localization facilitated skin dysplasias or skin tumors could in principle be selective
for neoplasias in this tissue, neoplasias of this cell type, oridentification of the tissue structure to which the peptides were
binding (see Supplemental Figure S1 at http://www.cancercell. neoplasias induced by these oncogenes or be general to neopla-
sias in various tissues and of various cell types and oncogenicorg/cgi/content/full/4/5/383/DC1).
To further evaluate the homing specificity of the displayed transformations. To begin investigating this question, we asked
whether the K14-HPV16 SCC-homing peptides, CGKRK andpeptides, we similarly analyzed pure peptides outside the con-
text of the phage particles. We injected both younger dysplasia- CDTRL, would home to the endothelium in tumors that are of
different tissue origins and/or are resident in different anatomicalbearing and older tumor-bearing K14-HPV16 mice with each of
the fluorescein-labeled peptides. After 10 min, both normal and locations. To this end, we examined three subcutaneous tumors
arising from inoculated tumor cell lines, two other transgenicneoplastic tissues were collected; tissue sections were prepared
and stained with antibodies to both CD31 and a second endo- mouse models of organ-specific tumorigenesis, and subcutane-
ously transplanted matrigel pellets embedded with VEGF andthelial marker, the cell-surface antigen MECA32. Similar results
were obtained with the two antibodies; the data for MECA32 bFGF. Each was assessed for selective binding to the neovascu-
lature of intravenously injected fluorescein-labeled peptidesare shown. Localizations of the intravenously infused peptides
and the antibody were visualized by two-color fluorescence (Figure 4; Supplemental Figure S3 on Cancer Cell website). We
observed distinctive homing specificities for the two peptidesmicroscopy. The fluorescein-labeled peptides colocalized with
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Figure 3. Fluorescein-labeled peptides colocalize with a vascular marker
Fluorescein-labeled peptides were intravenously injected into mice with dysplastic skin lesions or tumors, the mice were sacrificed 10 min later, and the
peptide localization was examined in tissue sections. Fluorescein-CSRPRRSEC colocalizes with MECA32 in the vasculature of dysplastic skin (A) but not in
tumor tissue (D). This peptide continues to recognize the vasculature of dysplastic skin in tumor-bearing mice (D inset). This peptide does not recognize
premalignant lesions (angiogenic islets) in RIP1-Tag2 mice. Fluorescein-labeled CGKRK and CDTRL peptides were not detected in dysplastic skin from 4- to
6-month-old mice (B and C), but colocalized with MECA32 in tumor vasculature (E and F). Original magnifications: 200–400.
in the various tumor microenvironments, but with one common- The two tumor peptides showed different homing to three
types of subcutaneously grown transplanted tumors. Fluores-ality: each homed to the neovasculature in subcutaneous matri-
gel pellets infused with a mixture of VEGF and bFGF. Neither cein-CGKRK peptide homed to cells in each of the three trans-
plant tumors (Figures 4C–4E), which arose from PDSC5, a K14-peptide homed to angiogenic islets (dysplasias) or tumors in
the RIP-Tag transgenic mouse model of pancreatic islet cell HPV16 tumor-derived cell line (Figure 4C), the MDA-MB-435
human breast cancer line (Figure 4D; Price et al., 1990), andcarcinoma (Hanahan, 1985) (Figures 4A and 4F), indicating that
the binding moieties for these peptides are not present in nor- the C8161 human melanoma line (Figure 4E; Bregman and
Meyskens, 1986). In contrast, the CDTRL peptide was not pres-mal, dysplastic, or pancreatic tumor vasculature. Interestingly,
both CGKRK and CDTRL did home to breast carcinomas in ent in the PDSC5 (Figure 4H) or MDA-MB-435 (Figure 4I) and
only accumulated in the melanoma xenograft (Figure 4J) and inanother transgenic model, the MMTV-PyMT mice (Guy et al.,
1992) (Figures 4B and 4G). Some of the positive cells appeared the skin overlying the melanoma xenograft tumor (Figure 4J
inset). Fluorescein-CGKRK localized in the cytoplasm and nucleito be circulation-accessible tumor cells (Figure 4G; Chang et
al., 2000), and they were negative for the Fc-II/III receptors of vascular cells identified as endothelial cells by their morphol-
ogy and by immunostaining for CD31 and MECA32 (exemplified(data not shown), suggesting that the peptide binding moiety
can have broader representation beyond tumor endothelial by Figure 4D). In addition, the peptide apparently extravasated
out of the vessels and became distributed along tendril-likecells. Both the CGKRK and CDTRL bind a range of cultured
tumor cells (Supplemental Table S1 online) in addition to homing structures and in tumor cell nuclei; it also accumulated to some
extent in avascular necrotic regions (exemplified by Figures 4B,to tumor endothelial cells in vivo. Further, the activated endothe-
lium in this type of mouse breast tumor shares molecular deter- 4C, and 4E). Given that all three tumors were growing subcuta-
neously, presumably by recruiting a neovasculature from theminants with SCCs of the skin as detected by these peptides,
ones that are not found in the RIP-Tag model of endocrine same normal vascular bed in the dermis, one can infer that cell
type and/or oncogenic stimulus is imparting different qualitiespancreatic cancer. This commonality is despite the fact that
squamous tumorigenesis in the skin was induced by the E6 and onto the vasculature and the tumor microenvironment, as re-
vealed by the differential homing patterns seen with these pep-E7 oncogenes of HPV16, while the islet tumors in RIP1-Tag2
were induced by the SV40 Tag oncogene, and the mammary tides. Furthermore, it is apparent that the matrigel extracellular
matrix in combination with VEGF and bFGF is sufficient to elicittumors in MMTV-PyMT mice were induced by the polyoma
middle T antigen. expression of the binding moieties for these homing peptides;
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Figure 4. Localization of fluorescein-labeled peptides in other tumors
Mice bearing various tumors were intravenously injected with fluorescein-labeled peptides from the tumor-homing phage and examined as in Figure 3.
The tissue sections were stained with MECA32 (shown with red fluorochrome) and CD31 (not shown). Fluorescein-CGKRK (A–E) was detected in 4 of the 5
tumor models examined; RIP1-Tag2 tumors (A) were negative. Some features are indicated by arrows, with the labels EC (for endothelial cell), TC (for tumor
cell), and Ne (for necrotic region). The CGKRK peptide was seen in endothelial cells and tumor cells appearing both in the cytoplasm and nucleus (B–E;
arrow in D). Fluorescein-CDTRL (F–J) was absent in the RIP1-Tag2 tumors (F), PDSCJ5 (H), and MDA-MB-435 (I), but present in MMTV-PyMT tumors (G) and
C8161 xenografts (J) tumors. In the C8161 xenografts, the positive cells were CD31-positive cells that were adhering and spreading on the lumenal surface
of the blood endothelial cells; the established endothelia were negative (indicated by the white arrow in J). The blood vessels in the skin surrounding the
C8161 xenograft tumor are also positive for fluorescein-CDTRL (J inset). In the MMTV-PyMT, fluorescein-CDTRL colocalized with CD31 and MECA32 and also
bound to cells within the vessel wall that were negative for MECA32, CD31, and the Fc-II/II receptors (G). Original magnifications: 200–400.
notably, the neovasculature is again recruited from the dermis. of the dysplastic lesions, the selectivity of its homing is attribut-
able to vascular changes during the carcinogenic progressionMoreover, the two growth factors used in the matrigel assay
have been implicated in the angiogenesis associated with squa- from normal skin to dysplasia to cancer. The accompanying
paper (Joyce et al., 2003) describes peptides with different se-mouse carcinogenesis of the skin in the K14-HPV16 model
(Arbeit et al., 1996; Coussens et al., 1999). quences that selectively recognize premalignant angiogenic is-
lets in RIP1-Tag2 mice. Thus, the vasculature of premalignant
lesions can be distinguished from that of malignant tumors ofDiscussion
the same lineage in two different tumor systems.
The tumor-specific peptide CGKRK showed the broadestIn the study described herein, we have used phage libraries to
selectivity, homing to all tumors growing in or under the skin,profile the vascular changes that take place during squamous
while the CSRPRRSEC and CDTRL peptides were selective forcarcinogenesis of the skin in a transgenic mouse model involv-
two of the four tumors tested. The three tumor-selective phageing the human papillomavirus type 16 oncogenes, which are
did not home to normal skin vasculature and showed variableimplicated as causative agents in human squamous cancers.
selectivity toward dysplasias of tumor-bearing mice. While allWe describe three peptides that distinguish between the neo-
three homed to transplant tumors and the VEGF/bFGF matri-vasculature in premalignant dysplastic lesions and malignant
gels, none accumulated in the angiogenic islet dysplasias ortumors. The peptides also distinguish both types of vasculature
solid tumors in the RIP1-Tag2 model of pancreatic islet carcino-from normal skin vasculature. The in vivo binding patterns also
genesis. The strain of mice used did not seem to affect thereveal molecular diversity in the vasculature of tumors of differ-
homing of these peptides, as evidenced by their homing toent origins and anatomical locations, consistent with predictions
tumors in different strains and their differential homing to tumorsbased on evident morphological differences (Roberts et al.,
within the same strain. For example, the CGKRK peptide homed1998).
to tumors in FVB/b, C57B16, and Balb/c-nu/nu, while the CDTRLThe CSRPRRSEC peptide, obtained by screening for hom-
homed to C8161 but not MDA-MB-435 tumors, each growinging to dysplastic skin lesions, clearly differentiated this class of
lesions from normal skin and from fully developed skin tumors. in Balb/c-nu/nu mice. In the companion manuscript, Joyce et
al. (2003) report a panel of peptides that home to the vasculatureMoreover, because the peptide localized to the endothelial cells
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of angiogenic islets and pancreatic islet carcinomas but not to phosphatidylserine receptor on macrophages mediates en-
the skin dysplasias or tumors in the HPV16 mice, nor to the gulfment (Fadok et al., 2000); this could explain CGKRK’s uptake
vasculature in several subcutaneous transplant tumors or in s.c. by the necrotic/apoptotic regions in the tumors (like shown in
matrigel plugs. Together, the data demonstrate that tumorigene- Figure 4B).
sis in different organs involves the induction of distinctive vascu- The KRK sequence is also found in exon 6 of human and
lar signatures as revealed by the selection of peptides displayed mouse VEGF-A and other VEGF homologs like the endocrine
on circulating phage. gland-specific protein Bv8 (LeCouter et al., 2003). Exon 6 is
A database search revealed a homology between our present in the highly basic, cell-associated forms of VEGF
CSRPRRSEC peptide and the C220SRPRR225 sequence in human (VEGF189 and VEGF206). Synthetic peptides corresponding to
kallikrein-9 (Yousef and Diamandis, 2000) and its mouse homo- exon 6 release both FGF-2 and VEGF from the cell surface
log (RIKEN Clone 1200016C12; Kawai et al., 2001), both prote- (Jonca et al., 1997) and inhibit VEGF binding and activity on
ases of the trypsin super family. These particular residues ap- HUVECs (Jia et al., 2001). A 24 residue basic peptide from exon
pear to be critical for the homing of the CSRPRRSEC peptide, 7 of VEGF165 has been expressed on phage and shown to bind to
as evidenced by the recovery of the CSRPRRSVC and heparan sulfate and home to the vasculature of subcutaneously
CSRPRRSWC variants in our selection. The Cys220 to Arg225 growing CT26 colon and MATB-III mammary adenocarcinomas
sequence of human kallikrein-9 forms a loop that is part of the (El-Sheikh et al., 2002). The homing of heparin binding peptides
entrance to the active site; its conformation is variable between to tumor vasculature may be explained by a greater accessibility
the different kallikreins and trypsin family members, affecting to heparan sulfates or the expression of other specific glycos-
substrate specificity (Gomis-Ruth et al., 2002). Our cyclic pep- aminoglycans. Indeed there are known cases of glycosamino-
tide could structurally resemble and functionally mimic this loop. glycans being preferentially expressed on the blood vessels of
In the kallikreins, Cys220 forms a disulfide bond with Cys190, tumors (Smetsers et al., 2003; Qiao et al., 2003). The functional
the cysteine next to the active site nucleophile Ser195, and all importance of this sequence in VEGF-A is suggested by the
kallikreins close this loop with a kink introduced by the invariant fact that mice engineered to express only VEGF120, which lacksPro226. Our peptide closes the loop by forming a disulfide bond. the ability to bind heparin, die within 2 weeks postpartum (Car-
Besides the sequence and structural identity, human kallikrein-9 meliet et al., 1999). The CGKRK peptide may have a similar
is known to be expressed in the skin (Yousef and Diamandis, specificity, as it recognized the vessels in each of the subcutane-
2000), and the protein has been reported to be a favorable ous tumors as well as the neovasculature induced in matrigel
prognostic marker in ovarian cancer, implying that it antagonizes
pellets implanted with VEGF and bFGF (Supplemental Figure
ovarian carcinogenesis (Yousef et al., 2001); moreover, several
S3 on Cancer Cell website).
kallikreins are antiangiogenic (Diamandis et al., 2000). Thus, the
Basic FGF binds to heparan sulfate and is also internalizedreceptor for the CSRPRRSEC peptide may be a kallikrein-9
by cells in a process that can be distinguished from internaliza-substrate or inhibitor that is expressed or localized at elevated
tion via FGF receptors (Roghani and Moscatelli, 1992), sug-levels on the angiogenic endothelia of dysplastic skin lesions
gesting that heparan sulfate binding could be responsible forbut then decreases with progression to squamous carcinomas.
internalization of the CGKRK peptide. Finally, KRK is a knownIn analogy, PSA (prostate-specific antigen or human kallikrein-3)
nuclear localization sequence (Craggs and Kellie, 2001; Zhoucan cleave plasminogen to generate angiostatin (Heidtmann et
et al., 1991), potentially explaining the nuclear localization ofal., 1999); kallikrein binding proteins like kallistatin are involved
the CGKRK peptide we observed. SCC induced in the skin byin angiogenesis (Miao et al., 2002) and kallikreins can exist as
HPV oncogenes could therefore differ from islet cell tumors incomplexes with endogenous inhibitors on the surface of cells
the composition or presence of glycosaminoglycans like he-(Yayama et al., 2003). The possible functional involvement of
paran sulfate, a possibility that deserves future investigation.this protease and its substrates and inhibitors in the HPV16
A similar shared specificity between tumor endothelial andmodel squamous carcinogenesis deserves future investigation.
tumor cells has been previously reported for two other tumor-The CGKRK tumor-homing peptide was found in association
homing peptides (Laakkonen et al., 2002; Porkka et al., 2002);with the luminal surface of the tumor endothelium, but also
these reported peptides are also internalized by cells and be-inside the tumor parenchyma after an intravenous injection. The
come localized to the nuclei. Tumor-homing peptides that pene-localization of the peptide within the tumor tissues was not
trate into the tumor and are internalized by overt cancer cellssimply a result of leakiness of the tumor vasculature to labeled
or tumor endothelial cells may be particularly well suited forpeptides because we did not see the same distribution with the
targeting therapeutic and imaging agents into tumors, lev-other fluorescein-labeled peptides, and only the CGKRK peptide
eraging their specificity and ability to accumulate substantivelybecame localized to the nuclei of the tumor cells.
therein.The CGKRK tumor-homing peptide has an overall charge
In summary, we describe peptides that target differentof 3 and is essentially composed of basic residues. This pep-
stages of tumor development in the K14-HPV16 model of squa-tide may bind by virtue of this charge and composition to cell
mous cell carcinoma of the skin. These peptides further revealsurface heparan sulfates and to phosphatidylserine. An 60
molecular differences between tumor types. Peptides such asnm in diameter T7 phage displaying 415 copies of this peptide
these and the receptor moieties they detect by their selectivewould resemble a cationic liposome; cationic liposomes bind
binding will contribute to our understanding of vascular hetero-to and are used as a marker of tumor vasculature (Thurston et
geneity and temporal changes that occur during multistageal., 1998). Cationic particles may bind to phosphatidylserine,
tumor development in different organs. This knowledge will pro-an anionic phospholipid that is on the surface of tumor endo-
vide avenues for developing improved diagnostic tools, includ-thelial cells and is accessible to circulation (Ran et al., 2002).
Phosphatidylserine is also a marker of apoptotic cells, and the ing ones affording early detection of premalignant lesions and
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squamous epithelial neoplasia in K14-human papillomavirus type 16 trans-asymptomatic early stage carcinomas, as well as for targeting
genic mice. J. Virol. 68, 4358–4368.therapeutics to those lesions.
Arbeit, J., Olson, D., and Hanahan, D. (1996). Upregulation of fibroblast
Experimental procedures growth factors and their receptors during multi-stage epidermal carcinogen-
esis in K14-HPV16 transgenic mice. Oncogene 13, 1847–1857.
Tumor-bearing and transgenic mice
Bergers, G., Javaherian, K., Lo, K., Folkman, J., and Hanahan, D. (1999).
To investigate homing to dysplasias, we used K14-HPV16 mice at 4–6
Effects of angiogenesis inhibitors on multistage carcinogenesis in mice.
months of age and with no macroscopic evidence of tumors. Tumor-bearing Science 284, 808–812.
K14-HPV16 mice were 9–12 months old with obvious ear or trunk tumors.
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., and Hanahan, D.RIP1-Tag2 mice were used at 12 weeks of age, when 100% had pancreatic
(2003). Benefits of targeting both pericytes and endothelial cells in the tumorislet tumors. MMTV-PyMT mice were 4–6 months old, bearing palpable
vasculature with kinase inhibitors. J. Clin. Invest. 111, 1287–1295.mammary tumors. Cells for subcutaneous inoculation to produce the trans-
plant tumors were cultured in 10% fetal calf serum (FCS) in Dulbecco’s Bregman, M., and Meyskens, F.J. (1986). Difluoromethylornithine enhances
Modified Eagle’s Media (DMEM). Tumors were generated by subcutaneously inhibition of melanoma cell growth in soft agar by dexamethasone, clone A
injecting 106 cells into the chest skin of FVB/n (PDSC5) or Balb/c nude (MDA- interferon and retinoic acid. Int. J. Cancer 37, 101–107.
MB-435 and C8161) mice. We used mice bearing s.c. transplant tumors
Burg, M., Pasqualini, R., Arap, W., Ruoslahti, E., and Stallcup, W. (1999).with an approximate diameter of 1 cm. PDSC5 tumors and MDA-MB-435
NG2 proteoglycan-binding peptides target tumor neovasculature. Cancerxenografts reached this size about 9 weeks post-injection while C8161 xeno-
Res. 59, 2869–2874.grafts took 3 weeks post-injection. The matrigel angiogenesis bioassay in-
volved inoculating Balb/c-nu/nu mice with a gelatinous plug composed of Carmeliet, P., and Jain, R. (2000). Angiogenesis in cancer and other diseases.
a mixture of 400 l of Matrigel (Becton Dickinson, Bedford, Massachusetts), Nature 407, 249–257.
100 ng of basic fibroblast growth factor, and 50 ng of vascular endothelial
Carmeliet, P., Ng, Y.S., Nuyens, D., Theilmeier, G., Brusselmans, K., Cornel-
growth factor (R&D Systems, Minneapolis, Minnesota) in a 450 l final vol-
issen, I., Ehler, E., Kakkar, V.V., Stalmans, I., Mattot, V., et al. (1999). Impaired
ume. There were three experimental groups, one for each of the three pep- myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the
tides, comprised of three mice in each group. The mice were injected i.v. vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat.
with 100 g of fluorescein-peptide 9 days post-implantation. All animal Med. 5, 495–502.
experiments were approved by the Animal Research Committees at the
Chang, Y.S., di Tomaso, E., McDonald, D.M., Jones, R., Jain, R.K., andBurnham Institute or University of California at San Francisco.
Munn, L.L. (2000). Mosaic blood vessels in tumors: Frequency of cancer cells
in contact with flowing blood. Proc. Natl. Acad. Sci. USA 97, 14608–14613.Ex vivo and in vivo phage selections
The selections were made with an NNK-encoded CX7C peptide library dis- Coussens, L., Hanahan, D., and Arbeit, J. (1996). Genetic predisposition and
played on Novagen’s T7 415-1b phage vector. The library had a diversity parameters of malignant progression in K14-HPV16 transgenic mice. Am.
of approximately 1  108. Phage selections and validations have been de- J. Pathol. 149, 1899–1917.
scribed (Hoffman et al., 2004; Laakkonen et al., 2002).
Coussens, L., Raymond, W., Bergers, G., Laig-Webster, M., Behrendtsen,
O., Werb, Z., Caughey, G., and Hanahan, D. (1999). Inflammatory mast cells
Immunofluorescence and immunohistochemistry up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes
Areas of skin, tumors, and various organs were collected and either fixed Dev. 13, 1382–1397.
in formalin, dehydrated through serial alcohols, and embedded in paraffin
Coussens, L., Tinkle, C., Hanahan, D., and Werb, Z. (2000). MMP-9 suppliedor directly embedded in OCT medium (Fisher Scientific). The K14-HPV16
by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103,dysplasia and tumors were graded by evaluating hematoxylin & eosin and
481–490.anti-keratin staining on 5 m paraffin sections under a light microscope
(Coussens et al., 1996). Rat anti-mouse CD31, rat anti-mouse MECA32, and Craggs, G., and Kellie, S. (2001). A functional nuclear localization sequence
anti-CD16/CD32 (FcRII and FcRIII; BD Pharmingen) were used for vascular in the C-terminal domain of SHP-1. J. Biol. Chem. 276, 23719–23725.
immunostaining on 10 m frozen sections. The anti-phage stainings and
Diamandis, E., Yousef, G., Luo, L., Magklara, A., and Obiezu, C. (2000). Thebiodistribution of fluorescein-labeled peptides were conducted as previously
new human kallikrein gene family: implications in carcinogenesis. Trendsdescribed (Hoffman et al., 2004; Laakkonen et al., 2002).
Endocrinol. Metab. 11, 54–60.
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